Medicines for Europe

What are the current opportunities for global biosimilar access, and how can regulatory convergence and reliance facilitate this process? 🌍 Leaders from global regulatory agencies will share their current biosimilar strategies and discuss opportunities to overcome existing obstacles, while exploring new ways to strengthen reliance procedures. 📅 Join our Biosimilars Medicines Conference on April 3-4, 2025, in Amsterdam to learn more about key regulatory developments. Don't miss out on this chance and gear up for the future of biosimilars! 🧪 ➡️ Register here: https://buff.ly/eOIvyIS ➡️ Programme: https://buff.ly/GCZfOqm

⚡️The new wastewater treatment EU directive imposes unfairly steep costs on pharmaceutical manufacturers. It threatens to wipe out many critical drugs from the market, says Adrian van den Hoven, Director General of Medicines for Europe.↙️ https://lnkd.in/ef2C_xPK

Streamlining clinical requirements will play a key role in 2025 as regions work to adapt the regulatory guidance on biosimilar development. 🧪 📅 Join us at our Biosimilar Medicines Conference on April 3-4, 2025, and hear from leading global regulatory agencies on how to shape a global path for straightforward and fit-for-purpose requirements. Come be part of a global effort for a more efficient framework for biosimilars development. See you soon in Amsterdam! ➡️ Register here: https://buff.ly/2hpR47Q ➡️ Programme: https://buff.ly/7l5Fq7X

How can smart pricing and procurement policies support biosimilar competition in Europe? 📊 As the dynamics of the biologics market evolve, bridging pricing, procurement practices and sustainability is key to promoting patient access with #BiosimilarMedicines. 📅 Don’t miss our Biosimilar Medicines Conference on April 3-4, 2025, in Amsterdam to learn more about biosimilar market and competition policy approaches. ➡️ See you at #BIOS25! Register here: https://buff.ly/41fghqP ➡️ Programme: https://buff.ly/3Qi6xFV 🧪

📌 The #CriticalMedicinesAct is out today, marking a major step towards strengthening Europe’s autonomy and ensuring access to essential off-patent medicines. This achievement follows calls from our sector and other stakeholders for decisive action to address medicine shortages, backed by the intense work of the Critical Medicines Alliance.   Why is the Critical Medicines Act so important? ✅ Defines procurement reform with dedicated tendering criteria to reward supply security in pricing and procurement. ✅ Invests in partnerships for EU-industry collaborations to boost EU competitiveness and APIs production. ✅ Establishes an EU-wide solidarity plan with strategic reserves and national stockpiling mandates to prioritise patient access.   Let’s ensure that the #CriticalMedicinesAct becomes central to EU medicines policy for long-term access and manufacturing stability.   ➡️ Read our PR: https://shorturl.at/HyxN6

How relevant is the biosimilar industry in Europe’s biotech ecosystem? At the crossroads of health and competitiveness, the biosimilar industry is a key player in both sustainable healthcare and a thriving strategic European biotech and biomanufacturing sector. 🔬 📅 Join us at the Biosimilar Medicines Conference #BIOS25 on April 3-4, 2025, in Amsterdam to discover essential biosimilar strategies for the future of Europe's biotech. ➡️ Don’t miss out - register today and secure your spot: https://buff.ly/41fghqP See you in Amsterdam! 🧪

📢 Medicines for Europe supports legal action from ten of its members against provisions in the Urban Wastewater Treatment Directive which puts access to medicines at risk. Generic medicines are the backbone of European healthcare systems, representing 7/10 dispensed medicines and 9/10 critical medicines while accounting for just 19% of pharmaceutical market value. The Extended Producer Responsibility system in the UWWTD disproportionately affects the producers of generic medicines. The increased cost from these risks makes them commercially unviable, causing medicine shortages and putting patients and public health at risk. Read the full announcement: https://buff.ly/shJbpSw

💡 Have you ever thought about how biosimilar competition creates an opportunity to expand patient access and reshape patient journeys in diseases like rheumatoid arthritis and asthma? By offering high-quality treatment, biosimilars are closing the gap and tackle inefficiencies in both care delivery and access. 🧪 Join us at the Biosimilar Medicines Conference 2025 to explore how biosimilars fuel improved patient outcomes beyond cost savings. 📅 April 3-4, 2025 📍 Amsterdam Schiphol Airport ➡️ Save your spot: https://buff.ly/tPcDMbD ➡️ Programme: https://buff.ly/riL3sku

🧪 #DidYouKnow that biosimilar medicines have already saved a total of €56 billion since 2006? And in 2024 alone, that number has reached an impressive €6 billion? Biosimilar competition is reducing healthcare costs and generating savings for reinvestment in better health outcomes. 🔬 Join us at our 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝟐𝟎𝟐𝟓 to learn more about the future of biosimilars and their role in healthcare. 📅 April 3-4, 2025 📍 Amsterdam Schiphol Airport Let’s uncover the full value of biosimilars! ➡️ Register: https://buff.ly/41fghqP ➡️ Programme: https://buff.ly/3Qi6xFV

Thanks for joining us at #RAC25! 🚀 We are wrapping up our Regulatory Affairs Conference, where industry experts and health authorities gathered for two days to explore the future of the regulatory landscape for off-patent medicines. A huge thank you to all our participants, speakers and partners for making #RAC25 a success and making a real impact on the conversation. 🔬 Together, we can ensure that current frameworks and policies fully reflect the value the off-patent industry contributes to public healthcare. We look forward to seeing you at upcoming events. Until then, let’s continue the conversation on shaping the future of the regulatory landscape! 🔄